In vitro activity of isavuconazole against 140 reference fungal strains and 165 clinically isolated yeasts from Japan
| Autor: | Jun Ohwada, Mikio Arisawa, Malcolm G. P. Page, Yukiko Inagaki, Masao Tsukazaki, Kazuko Kobayashi, Toshikazu Yamazaki, Isao Umeda, Nobuo Shimma, Toshihiko Fujii |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Azoles
Microbiology (medical) Antifungal Agents Pyridines Microbial Sensitivity Tests Aspergillus fumigatus Microbiology Japan Amphotericin B Yeasts Candida krusei Nitriles Humans Pharmacology (medical) Aspergillus terreus Candida albicans Cryptococcus neoformans biology Candida glabrata Blastomyces dermatitidis Broth microdilution Fungi General Medicine Reference Standards Triazoles bacterial infections and mycoses biology.organism_classification Infectious Diseases Mycoses |
| Zdroj: | International Journal of Antimicrobial Agents. 36:324-331 |
| ISSN: | 0924-8579 |
| DOI: | 10.1016/j.ijantimicag.2010.06.003 |
| Popis: | The in vitro susceptibilities of 140 laboratory reference strains of fungi, including type strains, and 165 clinical yeast isolates from Japan towards isavuconazole compared with fluconazole (FLC), itraconazole (ITC), voriconazole and amphotericin B were measured. Broth microdilution methods based on Clinical and Laboratory Standards Institute (CLSI) methods were used for yeasts, and RPMI-MOPS medium semi-solidified with 0.2% low-melting-point agarose based on CLSI guidelines was used for moulds. The range of isavuconazole minimum inhibitory concentrations (MICs) was 0.0004-0.21 mg/L for Candida albicans, 0.0036-0.4 mg/L for Candida glabrata, 0.023-0.058 mg/L for Candida krusei, 0.0026-0.032 mg/L for Cryptococcus neoformans, 0.1-0.39mg/L for Aspergillus fumigatus and 0.2-0.39 mg/L for Aspergillus terreus. Isavuconazole was as active as ITC against the dimorphic true pathogenic fungi, with a range of MICs from |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect